MedTrace Logo

Multimodal Machine Learning Characterization of Solid Tumors

NCT04687969 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-05-22

No results posted yet for this study

Summary

This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness.

This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)

Conditions

  • Adenocarcinoma of Prostate
  • Radical Prostatectomy
  • Hepatocellular Carcinoma (HCC)
  • Glioma
  • Renal Cell Carcinoma (RCC)
  • Prostate Cancer

Interventions

DRUG

[18F]DCFPyL

will either be administered by intravenous injection by bolus by a qualified nuclear medicine technician at the Martinos Center, or will be administered as part of a clinical PET/CT examination

RADIATION

PET/MRI scanner

PET/MRI Scan with \[18F\]DCFPyL as directed by protocol

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Ciprian Catana, MD, PhD

    lead OTHER

Principal Investigators

  • Ciprian Catana, MD, Ph.D · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-23
Primary Completion
2024-08-12
Completion
2024-08-12
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04687969 on ClinicalTrials.gov